Results 1 to 10 of about 91,698 (296)

Multiomics analysis of homologous recombination deficiency across cancer types [PDF]

Biomolecules & Biomedicine
There remains ongoing debate regarding the association of homologous recombination deficiency (HRD) with patient survival across various malignancies, highlighting the need for a comprehensive understanding of HRD's role in different cancer types. Based
Lin Dong, Lin Li, Linyan Zhu, Fei Xu, Rumeng Zhang, Qiushuang Li, Yong Zhu, Zhutian Zeng, Keshuo Ding   +8 more
doaj   +4 more sources

Pan-cancer landscape of homologous recombination deficiency [PDF]

Nature Communications, 2020
Cancers deficient in homologous recombination can benefit from treatment with poly ADP-ribose polymerase (PARP) inhibitors. Here, the authors generated a classifier that can predict homologous recombination deficiency from genomic data and suggest ...
Luan Nguyen, John W. M. Martens, Arne Van Hoeck, Edwin Cuppen   +3 more
doaj   +4 more sources

Homologous recombination deficiency and ovarian cancer [PDF]

European Journal of Cancer, 2016
The discovery that PARP inhibitors block an essential pathway of DNA repair in cells harbouring a BRCA mutation has opened up a new therapeutic avenue for high-grade ovarian cancers.
Drew, Y, Kristeleit, RS, Ledermann, JA
core   +5 more sources

Leveraging homologous recombination repair deficiency in sarcoma

EMBO Molecular Medicine, 2023
Personalised oncology is at the forefront of cancer research. The goal of personalised oncology is to selectively kill cancer cells while minimising side effects on normal tissue.
Dea Slade, Joanna I Loizou
doaj   +3 more sources

Targeting homologous recombination deficiency in uterine leiomyosarcoma

Journal of Experimental & Clinical Cancer Research, 2023
Background Uterine leiomyosarcoma (uLMS) is a rare and aggressive gynaecological malignancy, with individuals with advanced uLMS having a five-year survival of  0.2) but only two samples had a CHORD score > 50%, one of which had a homozygous pathogenic ...
Genevieve Dall, Cassandra J. Vandenberg, Ksenija Nesic, Gayanie Ratnayake, Wenying Zhu, Joseph H. A. Vissers, Justin Bedő, Jocelyn Penington, Matthew J. Wakefield, Damien Kee, Amandine Carmagnac, Ratana Lim, Kristy Shield-Artin, Briony Milesi, Amanda Lobley, Elizabeth L. Kyran, Emily O’Grady, Joshua Tram, Warren Zhou, Devindee Nugawela, Kym Pham Stewart, Reece Caldwell, Lia Papadopoulos, Ashley P. Ng, Alexander Dobrovic, Stephen B. Fox, Orla McNally, Jeremy D. Power, Tarek Meniawy, Teng Han Tan, Ian M. Collins, Oliver Klein, Stephen Barnett, Inger Olesen, Anne Hamilton, Oliver Hofmann, Sean Grimmond, Anthony T. Papenfuss, Clare L. Scott, Holly E. Barker   +39 more
doaj   +4 more sources

Assessing the association between homologous recombination deficiency scores and treatment response in localized and metastatic prostate cancer [PDF]

The Journal of Pathology: Clinical Research
The aim of this study was to evaluate the predictive value of homologous recombination deficiency scores for therapeutic efficacy in prostate cancer across various disease stages under different regimens.
Qiyu Zhu, Yifu Shi, Ting Wang, Qian Zheng, Xiuya Zhou, Zehua Tan, Junru Chen, Jingjing Guo, Haoyang Liu, Pengfei Shen, Hao Zeng, Jinge Zhao   +11 more
doaj   +2 more sources

Constitutional BRCA1 Methylation is associated with high level of tumoral BRCA1 methylation and homologous recombination deficiency in triple-negative breast cancer [PDF]

npj Breast Cancer
Tumoral BRCA1 promoter methylation occurs frequently in triple-negative breast cancer (TNBC) and contributes to homologous recombination deficiency (HRD).
Justine Pasanisi, Constance Lamy, Lolita Lecompte, Sophie Vacher, Mathias Schwartz, Abderaouf Hamza, Sandrine M. Caputo, Sabrina Ibadioune, Laura Courtois, Frédérique Berger, Vincent Cockenpot, Sylvain Baulande, Jean-Yves Pierga, Celine Callens, Samia Melaabi, Chrystelle Colas, Eric Pasmant, Maud Kamal, Célia Dupain, Nicolas Servant, Christophe Le Tourneau, Ivan Bièche   +21 more
doaj   +2 more sources

Homologous recombination deficiency in primary ER-positive and HER2-negative breast cancer [PDF]

Communications Medicine
Background Homologous recombination deficiency (HRD) originating from inactivation of genes like BRCA1/BRCA2 is a targetable abnormality common in triple-negative breast cancer (TNBC).
Helen R. Davies, Daniella Black, Anders Kvist, Kristín Sigurjónsdóttir, Ana Bosch, Ramsay Bowden, Yasin Memari, Ziqian Chen, Giuseppe Rinaldi, Frida Rosengren, Deborah F. Nacer, Srinivas Veerla, Lennart Hohmann, Nicklas Nordborg, Jari Häkkinen, Johan Vallon-Christersson, Åke Borg, Serena Nik-Zainal, Johan Staaf   +18 more
doaj   +2 more sources

Homologous recombination deficiency in pancreatic neuroendocrine tumors. [PDF]

Future Oncol
Aim: Pancreatic Neuroendocrine tumors (pNETs) are a heterogeneous group of neoplasms whose tumor biology is still little known. Thanks to next-generation sequencing, pathogenic mutations in base-excision-repair MUTYH gene and homologous recombination genes CHEK2 and BRCA2 seem to have a role in the development of pNETs.Research design & methods: We ...
Bardasi C, Tenedini E, Bonamici L, Benatti S, Bonetti LR, Luppi G, Cortesi L, Tagliafico E, Dominici M, Gelsomino F.   +9 more
europepmc   +4 more sources

Regulators of homologous recombination deficiency identified by machine learning using somatic multi-omics data [PDF]

Life Science Alliance
Using somatic multi-omics data and explainable artificial intelligence, this study identifies novel alterations underlying homologous recombination repair deficiency across cancers.
Renan Valieris, Lucas Rosa, Luan Martins, Alexandre Defelicibus, Dirce Maria Carraro, Diana Noronha Nunes, Emmanuel Dias-Neto, Rafael Rosales, Israel Tojal da Silva   +8 more
doaj   +2 more sources